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Abstract
Even in the era of percutaneous reperfusion therapy, left ventricular (LV) remodeling after myocardial infarction (MI) leading to
heart failure remains a major health concern. Contractile dysfunction of the infarcted myocardium results in an increased pressure
load, leading to maladaptive reshaping of the LV. Several percutaneous transcatheter procedures have been developed to deliver
devices that restore LV shape and function. The purposes of this review are to discuss the spectrum of transcatheter devices that
are available or in development for attenuation of adverse LV remodeling and to critically examine the available evidence for
improvement of functional status and cardiovascular outcomes.
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Introduction
Despite continuous improvements in acute and long-term
treatment of myocardial infarction (MI) over recent decades,
the resulting myocardial injury remains an important cause of
adverse left ventricular (LV) remodeling, which over time
progresses into the clinical syndrome of heart failure [1].
Typical for post-MI LV remodeling is dilatation, geometric
change (from ellipsoid to spherical), and scar formation [2].
Both functional and structural measures of adverse LV remod-
eling, such as LV ejection fraction (LVEF) and LV dimen-
sions, are associated with mortality and cardiovascular events
after MI [3–6]. The beneficial effects of drugs or medical
devices on LV remodeling measures have been associated
with reduced long-term mortality [7]. In this review, we will
focus on the role of percutaneous transcatheter delivered med-
ical devices on LV remodeling. The definition of Bmedical
device^ varies according to local regulations, but generally,
it is defined as an instrument, apparatus, software, or material
that is intended for use in the diagnosis, treatment, monitoring,
or prevention of disease [8]. It can be differentiated from a
drug by its mechanism of action, which is not pharmacologi-
cal, immunological, or metabolic. Numerous devices have
been developed that attempt to restore the LV shape and revert
adverse post-MI changes, intended to provide long-term ben-
efits in terms of survival and functional status. Here, we will
provide a critical overview of the empirical evidence
supporting the use of LV restoration devices at various stages
of LV remodeling post-MI, with a main focus on the transcath-
eter delivery route.
Remodeling after myocardial infarction
In the early stages after MI, influx of inflammatory cells leads
to the destruction of collagen and regional thinning of the
infarcted area [9]. The healing of necrotic tissue and formation
of granulation tissue involves interactions among inflamma-
tory cells such as macrophages, f ibroblasts , and
myofibroblasts [10]. As the infarcted region expands, cardiac
fibroblasts deposit collagen in the infarct zone, which leads to
scar formation and prevents further dilatation. Typical for
post-MI remodeling is an increase in LV volumes and a more
spherical LV shape due to a loss of myocytes and stretching of
the remaining myocytes by the addition of sarcomeres in se-
ries [11]. Theoretically, dilatation can be beneficial by main-
taining stroke volume through the Frank-Starling mechanism.
However, the LV radius and the inverse of wall thickness are
proportional with wall stress (law of Laplace). Consequently,
LV dilatation increases wall stress and extends the burden on
the remaining myocytes, leading to subendocardial myocardi-
al ischemia and ultimately causing more damage [12].
Moreover, impaired LV contractility and reduced cardiac out-
put after MI leads to the activation of neurohormonal
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pathways [13]. These pathways are thought to act as a way to
maintain cardiac output through inotropic and chronotropic
effects. However, these compensatory mechanisms result in
an increased workload for the remaining myocytes, leading to
progressive adverse remodeling. Drug therapies aimed at
preventing heart failure post-MI mostly target neurohormonal
pathways. Numerous studies have found evidence of a favor-
able effect of these drugs on parameters of LV remodeling and
patient outcome [2]. Progressive dilatation is associated with
larger infarct mass, nonscarred LV mass, and ongoing ische-
mia [14, 15]. It can lead to further hemodynamic conse-
quences such as functional mitral regurgitation (FMR), which
occurs in 20–25% of patients after MI and is associated with
higher mortality rates [16]. Patients with progressive LV dila-
tation will eventually develop symptoms of heart failure.
Despite very effective medical treatment options, the current
chance of developing heart failure within 5 years after MI is
17% in men and 21% in women above the age of 45 [17],
which occurs most distinctly in patients admitted with an an-
terior MI [18].
Guideline recommendations
Signs of LV remodeling can already be seen in the early stages
after MI, within hours to days [2]. Contemporary guidelines
recommend the use of transthoracic echocardiography (TTE)
within the first 3 days after MI, to assess LVEF [19, 20]. A
repeat TTE assessment 30–90 days after initial hospitalization
is recommended because cardiac function can still recover in
the case of myocardial stunning and hibernation. Cardiac
magnetic resonance imaging (CMR) and computed tomogra-
phy imaging (CT) are more suitable imaging modalities for
research as a smaller sample size is needed to detect changes
in LV structure, due to higher accuracy and reproducibility
[21]. Recommended long-term therapies post-MI are based
on cardiac rehabilitation, lifestyle interventions, and medical
therapy. Contemporary MI guidelines do not recommend the
use of transcatheter devices in long-term therapies post-MI
[19, 20]. In the most recent heart failure guidelines [22–24],
implantable cardioverter-defibrillators (ICDs), defibrillators
with cardiac resynchronization therapy (CRT-Ds), and cardiac
contractility modulation (CCM) are the only transcatheter de-
vices recommended in the treatment of heart failure. This
highlights that LV restoration devices have not yet been ac-
cepted as standard clinical practice.
Devices to reverse left ventricular remodeling
Short-term effects of drugs and devices on (reverse) LV re-
modeling are associated with reduced longer-term mortality
rates [7]. Consequently, LV remodeling parameters are often
used as alternatives or proxy variables for long-term mortality
in clinical trials, because a smaller number of patients and a
shorter follow-up are required to attain the same power. In the
1950s, the strong relation between adverse LVremodeling and
patient outcome led to the hypothesis that surgical restoration
of the original volume and ellipsoid shape of the LV could be
beneficial in cases of severe LV remodeling. In the following
paragraphs, we will discuss several surgical and transcatheter
devices (Table 1) that have been investigated in post-MI pa-
tients in attempts to restore the LV shape as well as its hemo-
dynamic and mechanical properties. The order of discussion is
based on the indication for use.
Dilated ischemic cardiomyopathy
The first surgical attempt at LV restoration was the
aneurysmectomy with a linear suture, first described by
Cooley et al. in 1958 [25] and developed over the years
[26]. The procedure was used in a selected group of patients
with previous anterior MI and an aneurysmatic LV. The Dor
procedure, using a circular suture and a pericardial patch that
was covered by the residual myocardium, was later deemed
superior [27]. In the STICH randomized controlled trial (N =
1000), CABG and surgical ventricular reconstruction reduced
LV end-systolic volume by 19%, compared with 6% by
CABG alone, but had no significant effect on mortality, hos-
pitalization for cardiac events, and 6-min walk test (6MWT)
distance [28]. A possible reason for this outcome proposed by
the authors is that surgical reduction of LV volume, in addition
to reducing wall stress, also reduces diastolic distensibility.
Several surgical LVrestoration techniques have been inves-
tigated in patients with dilated cardiomyopathy, including not
only ischemic but also idiopathic etiologies. In 1985, the first
successful dynamic cardiomyoplasty procedure was per-
formed, which was the surgical wrapping of an autologous
latissimus dorsi muscle around the heart, which was activated
by an external cardiomyostimulator for 10 weeks to gradually
transform muscle fibers from type II to type I [29]. A prospec-
tive study including 68 patients observed a small increase in
LVEF at 6 months (p = 0.05), but no significant change in
peak oxygen consumption or cardiac index [30]. The
cardiomyoplasty-skeletal muscle assist randomized trial (C-
SMART) aimed to randomize 400 patients, but was terminat-
ed prematurely due to problems with patient recruitment and
reimbursement. As opposed to autologous tissue, the LV can
also be wrapped with synthetic material. Ventricular restraint
therapy is the surgical placement of a multifiber polyester
mesh around the LV, designed for patients with a dilated car-
diomyopathy. It is intended to restore the ellipsoid shape of the
LVand alleviate wall stress. In the ACORN trial (N = 300), the
implanted device named the CorCap™ (formerly Acorn
Cardiovascular, St. Paul, MN, USA) had no significant effect
on 3- and 5-year mortality but did significantly reduce LVend-
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diastolic volume (LVEDV) up to 5 years after implantation,
consistent across strata with and without mitral valve replace-
ment [31–34]. It has to be noted that these results cannot be
extrapolated to post-MI patients, since only 10% of the includ-
ed patients had heart failure with an ischemic etiology.
Epicardial ventricular restoration
As an alternative to the invasive surgical ventricular recon-
struction method, a minimally invasive surgical technique
was designed to exclude the nonviable part of the LV in pa-
tients with LV dilatation and anteroseptal scarring. The
Revivent™ myocardial anchoring system (BioVentrix, San
Ramon, CA, USA), previously named the PliCath HF™, is
composed of polyester-covered titanium anchors (5 × 25 mm)
mounted on a polyethylene-ether-ether-ketone tether, which
are placed on the right side of the interventricular septum
and on the LV wall. The anchors are drawn together to allow
apposition of the LV free wall to the septum, thereby exclud-
ing the nonviable anteroseptal scar. Initial results in humans
(N = 11) demonstrate a stable reduction in LV volumes up to
12 months [35]. The Revivent system has received CE mark-
ing for commercial use in Europe.
Later developments of the device led to the introduction of
a transcatheter component and a minor name change to
Revivent-TC™ (transcatheter) system, also receiving CE
marking. The upgraded system is not completely transcathe-
ter-based, still requiring a less invasive left thoracotomy. From
outside the LV, a needle is used to puncture the LV wall, cross
the LV, and puncture the interventricular septum. The needle
position is monitored using fluoroscopy, and a Swan-Ganz
catheter is introduced in the right jugular vein to monitor ven-
tricular pressures. After reaching the right ventricle, the needle
is replaced with a sheath and a guidewire. The guidewire is
captured in the right ventricle by a snare from the Swan-Ganz
catheter and connected with the internal anchor. The external
anchor is placed from outside the LV wall. If necessary, addi-
tional pairs of anchors (2–3) are placed to achieve the desired
line of apposition. Injection of contrast in the LV is used to
confirm whether successful exclusion of the nonviable LV
segment has been achieved. The Revivent-TC system has
been successfully implanted in six sheep, successfully reduc-
ing LVESV, improving LVEF, and improving strain in border
and infarct regions [36]. Study results from 51 patients treated
with the Revivent and 20 patients treated with the Revivent-
TC have been presented in the form of an abstract but have not
yet been published in a peer-reviewed journal [37]. A prospec-
tive, multicenter, dual-arm pivotal study is currently aiming to
include 146 subjects, who will be randomized to the Revivent-
TC system or optimal medical therapy in a 2:1 ratio. Major
inclusion criteria are the presence of an acontractile scar in the
septal and anterior, apical or anterolateral regions of the LV,
viable myocardium in the remote regions, LVEF under 45%,
LVESVi larger than 50 ml/m2, and NYHA class II or higher.
Transcatheter ventricular partitioning
The umbrella-like Parachute® device (Cardiokinetix,
Redwood City, CA, USA) is intended to partition off the
akinetic or aneurysmatic portion of the LV in patients with
ischemic heart failure. The device is comprised of a
fluoropolymer (ePTFE) membrane stretched over a self-
expanding nitinol frame, ranging between 65 and 95 mm in
diameter when expanded. It is deployed into the LVapex and
stabilized by 2-mm anchors at the end of each strut of the
umbrella. The device provides efficacy by regional unloading
of the akinetic LVregion and global reduction of wall stress by
reducing LV dimensions. Before implantation, LV anatomy
has to be evaluated carefully, preferably by computed tomog-
raphy imaging (CT), because anatomical characteristics such
as prominent trabeculation or a BLV moderator band^ are
unsuitable for device implantation. The Parachute device has
received CEmarking for commercial use in Europe but is only
approved for investigational use in the USA.
The device has been investigated in several PARACHUTE
trials (Table 1). The PARACHUTE First-In-Human trial (N =
39), which took place in Europe and the USA simultaneously,
demonstrated safety and feasibility of the Parachute device in
heart failure patients with LVEF between 15 and 40% and a
dilated LV with an akinetic or dyskinetic anterior-apical wall
[38]. There was a stable and significant reduction in LVEDV
up to 3 years after implantation [39]. However, stroke volume
and LVEF were also significantly lower at 3 years compared
with measurements at baseline. The PARACHUTE III trial
was a prospective, nonrandomized observational study con-
ducted in Europe, including 100 subjects with similar inclu-
sion criteria to the First-In-Human trial [40]. Procedural suc-
cess was achieved in 97% of the subjects. LV volumes were
significantly reduced at 12 months, and mean 6MWT distance
improved from 372 m at baseline to 397 m (p < 0.01). During
12-month follow-up, cardiac mortality was 8.4%, device-
related major adverse cardiac cerebral events (MACCE) oc-
curred in 7.0%, heart failure hospitalizations in 24.1%, and
stroke in 3% of subjects. Even though patients were given
low-dose aspirin and warfarin for at least 12 months post
device implant, the echo core lab identified thrombus on the
device in 3.3% of the subjects at 12 months. The
PARACHUTE IV was the first randomized controlled trial,
aiming to include 478 patients with NYHA class III–IV, LVEF
between 15 and 35%, LV motion abnormalities, and LVanat-
omy appropriate for Parachute implantation assessed by CT
imaging and randomize to optimal medical therapy or
Parachute implantation [41]. The primary endpoint was death
or hospitalization for worsening heart failure. After including
331 subjects, the PARACHUTE IV trial was terminated in
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June 2017 (clinicaltrials.gov≠NCT01614652) and it is unclear
whether investigation of the device will be continued.
In addition to the primary study results, there have been
some interesting post hoc analyses. Hemodynamic assessment
after Parachute implantation demonstrated an acute increase in
stroke volume and mean aortic pressure [42]. A CT study
investigating diastolic parameters before and after Parachute
implantation observed that the Parachute device significantly
reduced diastolic parameters such as the ratio between
transmitral velocity in early diastole and early diastolic mitral
septal tissue velocity (E/E′), and this reduction was correlated
with improvement in NYHA functional class [43]. Another
CT study observed a favorable effect of the Parachute on mi-
tral valve geometry, by reducing interpapillary muscle dis-
tance and tenting height [44]. A pathology study investigated
seven Parachute devices after cardiac transplantation (N = 3)
and at autopsy after deaths that were not device related (N = 4)
[45]. The devices generally showed good healing by orga-
nized endocardial tissue growth on luminal and abluminal
surfaces of the membrane. Parachute devices of long duration
(> 2 years, N = 2) showed evidence of microscopic calcifica-
tion, which could in theory lead to fatigue and rupture of the
membrane on the long term.
The aforementioned study findings suggest that the
Parachute device could be beneficial by reducing cardiac di-
mensions and end-diastolic wall stress and improving cardiac
output. However, 3-year results demonstrate a reduction of
LVEF and stroke volume. Results from the PARACHUTE
IV trial will have to demonstrate the added benefit of the
Parachute device in addition to optimal medical therapy. It is
unclear whether the investigation and development of the de-
vice will be continued.
Ischemic mitral regurgitation
Several surgical LV techniques have been attempted to treat
ischemic FMR before the use of a transcatheter delivery route.
The Coapsys™ (formerly Myocor, Maple Grove, MN, USA)
device was designed to treat annular dilatation and papillary
muscle displacement in patients with FMR by connecting an
anterior and posterior epicardial pad with a subvalvular chord
through the LV cavity and subsequently reducing the
anteroposterior diameter by bearing load during the diastolic
phase. The RESTOR-MV randomized controlled study was
initiated, including patients referred for CABG with the pres-
ence of FMR [46]. Participants were stratified according to the
need for mitral valve repair, as assessed by the surgeon. They
were subsequently randomized to undergo either CABG (±
mitral repair) or CABG and Coapsys implantation. The study
was unfortunately terminated early due to insufficient
funding. The investigators did find a significant survival ad-
vantage for patients who received the Coapsys device in the
165 subjects that were included, even though controls showed
lower FMR grades during follow-up. In 2008, Edwards
Lifesciences (Irvine, CA, USA) purchased the rights for the
Coapsys device but since then has not revealed any plans for
continuing the investigation or further development of the
device.
Transventricular system
A transcatheter variant of the Coapsys, the iCoapsys™ repair
system, was designed for the same patient category with is-
chemic FMR. The device consisted of the same elements as
the original Coapsys (epicardial pads and a transventricular
chord) but was implanted using transcatheter delivery. It was
successfully implanted in 12 adult sheep, with no complica-
tions reported [47]. Prior to the start of a first-in-human study
in 2008, Edwards Lifesciences purchased the rights for the
iCoapsys device and discontinued the trial.
Similar to the iCoapsys repair system, the percutaneous
septal sinus shortening system or PS3 System™ has a bridge
element inside the LV cavity, but instead of being attached on
the epicardium, its anchors are placed on the right side of the
atrial septum and in the great cardiac vein. It has been inves-
tigated in an ovine tachycardia model (N = 19), successfully
improving cardiac output and reducing FMR grade and
septolateral diameter [48]. First-in-human implantations in
two patients, immediately prior to explantation during planned
clinically indicated surgical mitral valve repair, reduced
septal-lateral dimensions and FMR grade [49].
Transvenous and subannular annuloplasty
Transcatheter interventions targeting the mitral apparatus such
as percutaneous edge-to-edge mitral valve repair, percutane-
ous annuloplasty, and percutaneous mitral valve replacement
are being reviewed elsewhere in this issue. A retrospective
analysis of percutaneous edge-to-edge repair with the
MitraClip (Abbott Vascular, Menlo Park, CA, USA) in 106
patients with ischemic FMR showed a significant reduction of
left atrial volume at 1 year after implantation but no effect on
LV volumes [50]. In the EVEREST II trial, MitraClip was
associated with durable reduction of LVEDV up to 5 years,
but this trial included mostly patients with degenerative mitral
regurgitation [51]. In the following paragraph, we will discuss
several transcatheter techniques here that target the coronary
sinus system and the subannular space to reshape the LV with
an effect on the mitral apparatus (Table 1).
A transcatheter mitral annuloplasty by implantation of a
device in the coronary sinus (transvenous annuloplasty) has
the advantage that no atrial septum puncture is required to gain
access to the left heart. However, the coronary sinus is ana-
tomically at a distance from the mitral annulus, and in some
cases, the great cardiac vein passes over a coronary artery,
which can be compressed or occluded by the device. The
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Monarc (previously Viking) system (Edwards Lifesciences,
Irving, CA, USA) uses an implant with two self-expanding
anchors and a spring-like Bbridge,^ which was investigated in
72 patients of which 57% had a prior MI [52]. It was im-
planted in 59 patients (82%), and the primary safety endpoint
of freedom from death, tamponade, or MI was 91% at 30 days
and 82% at 12 months. A major issue in patients with im-
planted Monarc devices was coronary artery compression,
which was observed in 15 patients who underwent follow-
up angiography (30%), of which two presented with an acute
MI. Another alternative, the percutaneous transvenous mitral
annuloplasty (PTMA) device (formerly Viacor, Wilmington,
MA, USA) consists of a PTMA catheter and nitinol rods of
varying stiffness and is intended for patients with moderate to
severe FMR, NYHA class II–IV, and LVEF 20–50%. The
PTOLEMY-2 safety and feasibility trial included 43 subjects
in whom implantation was attempted, resulting in 30 success-
ful implantations of the device [53]. Unfortunately, four de-
vices had to be removed at a later stage and two periprocedural
deaths led to early termination of the trial by the sponsor. Also,
during long-term follow-up after implantation, late erosions of
the coronary sinus led to serious complications, in some cases
fatal [54, 55]. The most thoroughly investigated transvenous
annuloplasty device is the Carillon Mitral Contour System
(Cardiac Dimensions, Sydney, Australia), which uses an im-
plant that is composed of two self-expanding nitinol (nickel-
titanium alloy) anchors connected by a curvilinear segment
and delivered by a catheter via the right internal jugular vein,
previously described in more detail [56, 57]. There have been
three nonrandomized safety and efficacy studies conducted in
Europe, including patients with at least moderate FMR, LVEF
under 40%, NYHA functional class II or higher, and 6MWT
distance between 150 and 450 m [56–58]. Where reported,
FMR etiology was ischemic in 55–60% of patients. Study
results demonstrated consistent low 30-day major adverse
event rate (between 2 and 13%), significant reductions of
regurgitant volume, and improvements in 6MWT distance.
During follow-up evaluation in the TITAN trial, nine subjects
(25% of subjects with a permanent implanted device) were
observed to have a fractured anchor wire [57]. Although this
was not linked to the occurrence of clinically relevant adverse
events, the device (XE2) was modified to help reduce strain in
the proximal anchor. The modified device (mXE2) was eval-
uated in the TITAN II trial, resulting in no more fractured
devices [58]. The REDUCE FMR multicenter randomized
controlled double-blind trial is currently randomizing 180 pa-
tients to the Carillon Mitral Contour System or optimal med-
ical therapy in a 3:1 ratio, with primary efficacy endpoint
being improvement in regurgitant volume at 12 months,
assessed by an independent echocardiography core laboratory
blinded to patient data [59]. A more recent device, the mitral
loop cerclage (Tau-PNUMedical, Pusan, Korea), consists of a
tension element made of stainless steel and an arch-like
coronary artery protection element. The device creates a loop
through the coronary sinus and the right ventricle across the
interventricular septum, covering the full circumference of the
mitral annulus and applying circumferential tension. Because
of the coronary artery protection device, it is suitable for a
wider range of patients than the previously described devices.
It has been investigated in a first-in-human feasibility study on
five subjects with severe FMR and NYHA class III or IV,
reporting a successful implantation in four subjects, reducing
LVEDVand regurgitant volume [60]. Future studies will have
to determine whether a transvenous mitral annuloplasty can be
a feasible treatment for patients with ischemic FMR (Table 1).
The AccuCinch (Ancora Heart, Santa Clara, CA, USA)
transcatheter direct mitral valve annuloplasty (or
ventriculoplasty) system is designed to place anchors in the
subannular space [68]. Cinching of these anchors reduces both
basal LV and mitral annular dimensions. Anchors are deliv-
ered by anchor delivery catheters that are introduced through a
modular guide tunnel via the femoral artery. A safety and
feasibility trial is currently conducted, aiming to include a total
of 40 patients.
Early phase after myocardial infarction
LV reconstruction techniques are intended to (partially)
revert the changes to LV mechanical properties caused
by myocardial injury. Ideally, this should be done during
the early stages after MI, when scar formation, regional
thinning of the myocardium, and LV dilatation can still
be prevented. Most of the aforementioned studies, how-
ever, exclude patients within 90 days after MI. The rea-
soning behind this is that adverse LV remodeling can
largely be reversed due to myocardial hibernation. Early
assessment of myocardial viability by late enhancement
CMR could be used to assess the risk of progressive LV
remodeling and the need for an early intervention [69]
(Fig. 1).
Biomaterial injection and infusion
As stated earlier, MI induces degradation of extracellular ma-
trix, which reduces elasticity of the myocardium. A proposed
option to restore the mechanical properties of the myocardium
is by injecting biomaterials into the myocardium, which could
serve as an artificial extracellular matrix. Biomaterial scaffolds
incorporating stem cells were not included in this review, be-
cause we considered cellular products to be a different cate-
gory. Several types of biomaterial injections have been tested
in animal studies. The effect of calcium hydroxyapatite micro-
sphere (CHAM) injections in infarcted myocardium was in-
vestigated in 31 sheep and appeared to limit LV dilatation and
improve LVEF up to 4 weeks after ligation of the left anterior
descending coronary artery [63]. A follow-up study
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randomized 24 adult male sheep to receive either saline or
CHAM injection after ligation of the left anterior descending
coronary artery [64]. In addition to improving LVEF and re-
ducing LVEDV compared to controls, the authors observed a
reduction of collagen content in the sheep that received
CHAM injections. A more recent study randomized 25
Yorkshire swine to receive either 20 normal saline or
CHAM injections at 30 min after ligation of the circumflex
artery [65]. The animals receiving CHAM injections showed
reduced infarct thinning and progressive improvement in bor-
der zone and global LV function. To date, no studies in
humans have been reported.
Another widely investigated biomaterial is injectable
myocardial matrix hydrogel, which is produced by
decellularizing porcine myocardial tissue and processing
it to form a myocardial matrix with the ability to gel
upon injection. Myocardial matrix hydrogel injections
have been investigated in 58 rats undergoing ischemia
reperfusion followed by injection of either the hydrogel
or saline 2 weeks later [70]. The hydrogel increased
endogenous cardiomyocytes in the infarct area and
maintained cardiac function without inducing arrhyth-
mias. Similar results were observed in a study on 10
pigs, using transcatheter injections [71]. The authors al-
so investigated the hemocompatibility of porcine myo-
cardial matrix with human blood and observed no effect
on clotting times. Possible mechanisms underlying the
benefit of myocardial matrix injections are an altered
inflammatory response, reduced cardiomyocyte apopto-
sis, enhanced neovascularization, diminished cardiac hy-
pertrophy and fibrosis, and enhanced recruitment of pro-
genitor cells [72]. A phase 1 study is currently enrolling
post-MI patients to study the safety of transcatheter ad-
ministration of myocardial matrix hydrogel in humans.
A less frequently investigated type of hydrogel that
has been investigated in animal studies post-MI is in-
jectable hyaluronic acid-based hydrogel, which appears
to reduce myofiber stress and limit adverse LV remod-
eling [66, 67].
As a less invasive alternative to intramyocardial injec-
t ions, biomater ia ls can also be adminis tered by
intracoronary infusion. In 27 post-MI patients, the
intracoronary administration of 2 ml of 1% sodium alginate
plus 0.3% calcium gluconate within 7 days after MI was
feasible and tolerated well [61]. The infusion is assumed to
permeate infarcted tissue, where it cross-links into a hydro-
gel and forms a bioabsorbable cardiac matrix (BCM). The
PRESERVATION I randomized controlled trial random-
ized 303 patients at 2–5 days after ST-elevation MI
(STEMI) with TIMI (Thrombolysis In Myocardial
Infarction) flow grade 3 in the infarct-related coronary ar-
tery to intracoronary application of BCM or saline in a 2:1
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to demonstrate a significant difference in adverse clinical
event rate or change in LVEDVi from baseline to 6 months,
assessed by an independent echocardiography core labora-
tory blinded to patient data. However, administration of a
larger volume of BCM or alternative timing of administra-
tion could be worth further investigation. The surgical ad-
ministration of injectable calcium alginate hydrogel
(Algisyl), similar to BCM, has been investigated in pa-
tients with advanced heart failure [73]. A total of 78 pa-
tients with LVEF ≤ 35%, peak VO2 between 9.0 and
14.5 ml/kg/min, and a dilated LV were randomized to treat-
ment with 15 injections or optimal medical therapy.
Statistically significant improvements were observed for
VO2, 6MWT distance, and NYHA functional class.
There was, however, no sham procedure performed in the
control group, and there were nine deaths in the Algisyl
group (22.5%) vs. four deaths in the control group
(10.5%), although the trial was not powered to assess
mortality.
Clinical trial design
Study endpoints of clinical trials investigating the effect of LV
restoration or enhancing devices should be carefully consid-
ered. Because LV dimensions are artificially altered, they
should be seen as independent variables. Parameters of LV
remodeling such as LVESVi and LVEDVi have to be used
Fig. 1 An overview of the
discussed transcatheter left
ventricular restoration devices,
grouped by indication for use
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to assess the efficacy of the procedure and should not be
interpreted as a proxy variable for patient outcome.
Preferable outcome measures to be considered for large
pivotal trials are (cardiovascular) mortality, major ad-
verse cardio- and cerebrovascular events , and
(non-)heart fai lure hospital izat ions [74]. Other
(secondary) endpoints to be considered are functional
capacity, severity of dyspnea on visual analogue scale
(VAS) or Likert scale, and quality of life assessments.
Another important consideration for pivotal randomized
controlled trials investigating transcatheter restoration
devices is the use of a sham procedure in the control
group. A recent meta-analysis suggested that mean im-
provement in sham groups for percutaneous procedures
can be as large as 64%, highlighting the strong placebo
effects [75]. A striking example of the importance of a
sham procedure is the SYMPLICITY HTN-3 sham con-
trolled trial, which was not able to reproduce the blood
pressure-lowering effects of catheter-based renal artery
denervation that earlier nonsham controlled trials had
observed [76]. A final consideration for device trials is
that follow-up after initial results should be extended to
5 years to investigate the long-term effects.
Future perspectives
In May 2017, new European medical device regulations
(2017/745) were entered into force [77]. The new regu-
lations increase safety and performance requirements of
high-risk devices and the level of supervision of notified
bodies. High-risk devices will have to be evaluated by a
panel of clinical experts, devices will have to demon-
strate equivalence to other safe devices in the market,
and more detail will be required in clinical evaluation
reports. Relevant information on medical devices will be
collected in the European Database on Medical Devices
(EUDAMED), and all devices will require a mandatory
Unique Device Identification (UDI) so that they can be
traced. There will be stricter requirements for post-
market surveillance, including annual safety update re-
ports which have to be assessed by a notified body.
There is a transition period until May 2020 during
which notified bodies will be designated under the
new rules. Before the end of the transition period, all
medical devices must be recertified under the new reg-
ulations. It will prove to be challenging for small inno-
vative medical device manufacturers to comply with the
new requirements.
Patient selection could be very important in determining
which patients could have clinical benefit from implanta-
tion of a LV restoration device. As the potential benefit of
LV restoration at early stages after MI is theoretically
larger, early assessment of myocardial viability after MI
could be a tool for risk stratification and determining the
need for an early intervention. In patients with heart fail-
ure, an elementary requirement to be considered for device
implantation is that medical therapy has been optimized
according to heart failure guidelines, as this has been prov-
en to promote reverse LV remodeling. A potential predictor
of poor outcome could be pre-existing diastolic dysfunc-
tion, as using a device to artificially reduce the LV volume
might further increase LV myocardial stiffness. The lack of
consensus on the definition of diastolic dysfunction makes
investigating this very challenging. A post hoc analysis of
the association between pre-existing diastolic dysfunction
and survival in earlier randomized controlled trials on sur-
gical LV restoration could provide more insight.
Improvements in safety and efficacy of mechanical circu-
latory support devices such as left ventricular assist devices
(LVAD) might reduce the need for LV restoration devices in
the future. The 6-month results of the HeartMate 3 Left
Ventricular Assist System (Abbott, Abbott Park, IL, USA)
demonstrate a survival free of any nonsurgical bleeding,
thromboembolic event, pump thrombosis, or neurological
event in 69% of patients [78]. Progressive improvements
could gradually move the indication for use toward earlier
stages of heart failure.
Conclusions
Both surgical and transcatheter LV restoration tech-
niques consistently demonstrate improvements in
quality-of-life measures and functional status but cur-
rently fail to demonstrate a clear survival benefit.
Study designs for surgical LV restoration techniques
are limited to patients that are already planned for sur-
gery with thoracotomy, such as CABG. The noninvasive
nature of transcatheter procedures allows for easier pa-
tient selection and identification of independent device-
related effects. Selection of suitable study endpoints and
the use of a sham control procedure is essential in clin-
ical trial design. Transcatheter LV restoration devices
show promising results in both animal and in-human
studies at different stages of adverse LV remodeling
after MI. The Parachute device could be beneficial in
heart failure patients with a recent anterior MI, poor
systolic function, and a suitable LV anatomy by reduc-
ing cardiac dimensions and end-diastolic wall stress.
The PARACHUTE IV randomized controlled trial will
have to demonstrate additional benefit on top of optimal
medical therapy, but it is uncertain whether investigation
of the device will be continued. Most of the benefit of
LV restoration devices is theoretically gained at early
stages after MI, using devices that can alter LV
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mechanical properties, such as transcatheter injection of
biomaterials in the infarcted region. This will require
proper selection of patients at risk of adverse LV re-
modeling. In the near future, it will prove to be chal-
lenging for small medical device manufacturers to com-
ply with requirements of the 2017 European medical
device regulations.
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